Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Authors
Demetri, GReichardt, P
Kang, Y
Blay, J
Rutkowski, P
Gelderblom, H
Hohenberger, P
Leahy, Michael G
von Mehren, M
Joensuu, H
Badalamenti, G
Blackstein, M
Le Cesne, A
Schöffski, P
Maki, R
Bauer, S
Nguyen, B
Xu, J
Nishida, T
Chung, J
Kappeler, C
Kuss, I
Laurent, D
Casali, P
Affiliation
Ludwig Center at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.Issue Date
2013-01-26
Metadata
Show full item recordAbstract
Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.Citation
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. 2013, 381 (9863):295-302 LancetJournal
LancetDOI
10.1016/S0140-6736(12)61857-1PubMed ID
23177515Type
ArticleLanguage
enISSN
1474-547Xae974a485f413a2113503eed53cd6c53
10.1016/S0140-6736(12)61857-1